POTENTIAL
Ozempic®—the once-weekly treatment
unifying superior efficacy1-4,28,30 and CV benefits1,5
Help your patients with type 2 diabetes
For adults with type 2 diabetes and established CVD
2018 ADA/EASD consensus report recommends
GLP-1 RA therapy with proven CV benefit6
SUPERIOR
GLYCAEMIC
CONTROL1,2,28,30*
SUPERIOR AND
SUSTAINED
WEIGHT LOSS1,2,5,28,30*
PROVEN
CV BENEFITS1,5†
CV=cardiovascular; CVD= cardiovascular disease; ADA=American Diabetes Association;
EASD=European Association for the Study of Diabetes; GLP-1 RA=glucagon-like peptide-1 receptor agonist.
*Results apply to Ozempic® across SUSTAIN trials, which included placebo, Januvia®,
Trulicity®, Bydureon®, Lantus®, Invokana® and Victoza®.1,2,28,30
†In SUSTAIN 6, Ozempic® reduced CV risk (CV death, nonfatal myocardial infarction [MI] or nonfatal stroke)
versus placebo in patients with type 2 diabetes at high CV risk treated with standard of care.1